CD19 and breast carcinoma: For example, studies have reported CD19+CD25hi BREG cells that support T regulatory (TREG) cell function in vitro in co-culture experiments, but also several populations of BREG cells which suppress an anti-tumour response in cancer such as those expressing granzyme B in solid tumour infiltrates, and CD19+CD24+CD38+ cells in breast cancer [116–118].